首页> 美国卫生研究院文献>CPT: Pharmacometrics Systems Pharmacology >A General Framework for Assessing In vitro/In vivo Correlation as a Tool for Maximizing the Benefit‐Risk Ratio of a Treatment Using a Convolution‐Based Modeling Approach
【2h】

A General Framework for Assessing In vitro/In vivo Correlation as a Tool for Maximizing the Benefit‐Risk Ratio of a Treatment Using a Convolution‐Based Modeling Approach

机译:评估体外/体内相关性的通用框架作为使用基于卷积的建模方法最大化治疗风险比的工具

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The net benefit of a treatment can be defined by the relationship between clinical improvement and risk of adverse events: the benefit‐risk ratio. The optimization of the benefit‐risk ratio can be achieved by identifying the most adequate dose (and/or dosage regimen) jointly with the best‐performing in vivo release properties of a drug. A general in silico tool is presented for identifying the dose, the in vitro and the in vivo release properties that maximize the benefit‐risk ratio using convolution‐based modeling, an exposure‐response model, and a surface response analysis. A case study is presented to illustrate how the benefit‐risk ratio of methylphenidate for the treatment of attention deficit hyperactivity disorder can be maximized using the proposed strategy. The results of the analysis identified the characteristics of an optimized dose and in vitro/in vivo release suitable to provide a sustained clinical response with respect to the conventional dosage regimen and formulations.
机译:治疗的净收益可以通过临床改善与不良事件风险之间的关系来定义:收益风险比。可以通过确定最适当的剂量(和/或剂量方案)以及最佳的药物体内释放特性来实现受益风险比的优化。提出了一种通用的计算机模拟工具,用于识别剂量,体外和体内释放特性,这些特性可以使用基于卷积的模型,暴露-响应模型和表面响应分析来最大化受益风险比。提出了一个案例研究,以说明使用所提出的策略如何最大程度地提高哌醋甲酯用于治疗注意力不足过动症的受益风险比。分析结果确定了最佳剂量和体外/体内释放的特征,其相对于常规剂量方案和制剂而言可提供持续的临床反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号